UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 155 filers reported holding UNIQURE NV in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,568,250 | -28.8% | 1,575,000 | +21.6% | 0.82% | -22.9% |
| Q2 2023 | $14,840,700 | -32.6% | 1,295,000 | +18.5% | 1.07% | -35.0% |
| Q1 2023 | $22,013,020 | -15.2% | 1,093,000 | -4.5% | 1.64% | -25.4% |
| Q4 2022 | $25,957,150 | +0.7% | 1,145,000 | -16.6% | 2.20% | +10.3% |
| Q3 2022 | $25,768,000 | +2.0% | 1,373,600 | +1.4% | 1.99% | +11.6% |
| Q2 2022 | $25,257,000 | +3.2% | 1,355,000 | 0.0% | 1.78% | +36.1% |
| Q1 2022 | $24,485,000 | -5.8% | 1,355,000 | +8.1% | 1.31% | +37.1% |
| Q4 2021 | $25,992,000 | +14.1% | 1,253,200 | +76.2% | 0.96% | +7.7% |
| Q3 2021 | $22,771,000 | +161.7% | 711,355 | +151.8% | 0.89% | +195.0% |
| Q2 2021 | $8,701,000 | -8.6% | 282,516 | 0.0% | 0.30% | -40.3% |
| Q1 2021 | $9,518,000 | -45.1% | 282,516 | -41.1% | 0.50% | -38.5% |
| Q4 2020 | $17,343,000 | -1.9% | 480,000 | 0.0% | 0.82% | -36.7% |
| Q3 2020 | $17,679,000 | -18.3% | 480,000 | 0.0% | 1.30% | -25.2% |
| Q2 2020 | $21,629,000 | -53.5% | 480,000 | -51.0% | 1.73% | -36.8% |
| Q1 2020 | $46,502,000 | +32.4% | 980,000 | +100.0% | 2.74% | -31.8% |
| Q4 2019 | $35,113,000 | +56.5% | 490,000 | -14.0% | 4.02% | +61.0% |
| Q3 2019 | $22,435,000 | -42.6% | 570,000 | +14.0% | 2.50% | -29.8% |
| Q2 2019 | $39,075,000 | -12.7% | 500,000 | -33.3% | 3.55% | -12.4% |
| Q1 2019 | $44,738,000 | +43.1% | 750,000 | -30.9% | 4.06% | +114.1% |
| Q4 2018 | $31,270,000 | -12.7% | 1,085,000 | +10.3% | 1.90% | -18.5% |
| Q3 2018 | $35,811,000 | -9.8% | 984,100 | -6.3% | 2.32% | -13.3% |
| Q2 2018 | $39,690,000 | +60.9% | 1,050,000 | 0.0% | 2.68% | +23.0% |
| Q1 2018 | $24,675,000 | +20.0% | 1,050,000 | 0.0% | 2.18% | +25.8% |
| Q4 2017 | $20,570,000 | +104.1% | 1,050,000 | 0.0% | 1.73% | +63.7% |
| Q3 2017 | $10,080,000 | +32.9% | 1,050,000 | -14.3% | 1.06% | -5.2% |
| Q2 2017 | $7,582,000 | +39.6% | 1,224,936 | +30.3% | 1.12% | +32.3% |
| Q1 2017 | $5,433,000 | +252.8% | 940,000 | +241.8% | 0.84% | +667.3% |
| Q4 2016 | $1,540,000 | – | 275,001 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |